PMID- 37626745
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230828
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 11
IP  - 8
DP  - 2023 Aug 11
TI  - Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies.
LID - 10.3390/biomedicines11082249 [doi]
LID - 2249
AB  - Inflammatory bowel disease (IBD) is a term used to represent a group of chronic, 
      relapsing inflammatory disorders of the gastrointestinal tract. Crohn's disease 
      (CD) and ulcerative colitis (UC) are the two major clinical forms. The global 
      incidence and prevalence of IBD have increased over the last 2-4 decades. Despite 
      the specific etiopathogenesis of IBD still being unknown, it is widely recognized 
      that immunological, genetic, and environmental factors are implicated. A greater 
      understanding of the multiple signaling pathways involved has led to the 
      development of biologic therapies in the last two decades. Although these 
      treatments have dramatically transformed the course of IBD, there is not a 
      definitive cure and available therapies may cause adverse events (AEs), limiting 
      their use, or have an inadequate effect in some patients. In this context, 
      emerging therapies addressing new specific pathogenetic mechanisms have shown 
      promising efficacy and safety data in early clinical trials. The purpose of this 
      review is to highlight the available clinical trial data for these new drugs, 
      such as more preferential JAK inhibitors, anti-IL-23 antibodies, 
      sphingosine-1-phosphate receptor modulators, anti-integrin therapies, and other 
      small molecules that are currently under research. We will emphasize the 
      potential significance of these agents in shaping future treatment options.
FAU - Bretto, Elisabetta
AU  - Bretto E
AD  - Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
AD  - Unit of Gastroenterology, Citta della Salute e della Scienza di Torino-Molinette 
      Hospital, 10126 Turin, Italy.
FAU - Ribaldone, Davide Giuseppe
AU  - Ribaldone DG
AUID- ORCID: 0000-0002-9421-3087
AD  - Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
AD  - Unit of Gastroenterology, Citta della Salute e della Scienza di Torino-Molinette 
      Hospital, 10126 Turin, Italy.
FAU - Caviglia, Gian Paolo
AU  - Caviglia GP
AUID- ORCID: 0000-0002-0529-9481
AD  - Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
FAU - Saracco, Giorgio Maria
AU  - Saracco GM
AUID- ORCID: 0000-0001-5310-4143
AD  - Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
AD  - Unit of Gastroenterology, Citta della Salute e della Scienza di Torino-Molinette 
      Hospital, 10126 Turin, Italy.
FAU - Bugianesi, Elisabetta
AU  - Bugianesi E
AUID- ORCID: 0000-0002-0502-4381
AD  - Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
AD  - Unit of Gastroenterology, Citta della Salute e della Scienza di Torino-Molinette 
      Hospital, 10126 Turin, Italy.
FAU - Frara, Simone
AU  - Frara S
AD  - Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
AD  - Unit of Gastroenterology, Citta della Salute e della Scienza di Torino-Molinette 
      Hospital, 10126 Turin, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230811
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC10452708
OTO - NOTNLM
OT  - Crohn's disease
OT  - JAK inhibitors
OT  - anti-integrins
OT  - anti-interleukin-23 antibodies
OT  - inflammatory bowel disease
OT  - novel therapies
OT  - sphingosine-1-phosphate receptor modulators
OT  - ulcerative colitis
COIS- The authors declare no conflict of interest.
EDAT- 2023/08/26 10:42
MHDA- 2023/08/26 10:43
PMCR- 2023/08/11
CRDT- 2023/08/26 01:01
PHST- 2023/06/30 00:00 [received]
PHST- 2023/08/02 00:00 [revised]
PHST- 2023/08/08 00:00 [accepted]
PHST- 2023/08/26 10:43 [medline]
PHST- 2023/08/26 10:42 [pubmed]
PHST- 2023/08/26 01:01 [entrez]
PHST- 2023/08/11 00:00 [pmc-release]
AID - biomedicines11082249 [pii]
AID - biomedicines-11-02249 [pii]
AID - 10.3390/biomedicines11082249 [doi]
PST - epublish
SO  - Biomedicines. 2023 Aug 11;11(8):2249. doi: 10.3390/biomedicines11082249.